Cargando…
Bezlotoxumab: an emerging monoclonal antibody therapy for prevention of recurrent Clostridium difficile infection
Clostridium difficile infection (CDI) is the most common health care-acquired infection associated with high hospital expenditures. The incidence of subsequent recurrent CDI increases with prior episodes of CDI, 15%–35% risk after primary CDI to 35%–65% risk after the first recurrent episode. Recurr...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove Medical Press
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5779312/ https://www.ncbi.nlm.nih.gov/pubmed/29403263 http://dx.doi.org/10.2147/BTT.S127099 |